Biologic relief without the price tag: the promise of omlcylo in atopic asthma and chronic spontaneous urticaria

Omlyclo (omalizumab-igec), the first FDA-approved biosimilar to omalizumab (Xolair) in the United States, was approved on 7 March 2025, for multiple indications including atopic asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria (CSU). Functioning as an anti-IgE monoclonal antibody, Omlyclo binds free IgE, preventing its interaction with FcεRI receptors on mast cells and basophils, thereby reducing inflammatory responses. Clinical trials, including a pivotal global Phase 3 study in CSU, demonstrated comparable efficacy to Xolair with a significantly reduced cost, enhancing accessibility for patients. While generally well tolerated, reported side effects include pruritus, vertigo, and gastrointestinal disturbances, with rare concerns regarding malignancy risk requiring further long-term evaluation. The availability of this cost-effective biosimilar marks an important milestone in expanding biologic treatment access for patients with allergic asthma and CSU.